Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average Target Price from Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been assigned a consensus rating of “Hold” from the six analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.3333.

A number of brokerages have issued reports on AUTL. Zacks Research downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 21st. Needham & Company LLC reduced their target price on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen cut Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th.

Autolus Therapeutics Trading Up 2.8%

Shares of Autolus Therapeutics stock opened at $1.46 on Friday. The company has a market capitalization of $388.56 million, a P/E ratio of -1.76 and a beta of 1.98. The stock has a fifty day simple moving average of $1.58 and a 200 day simple moving average of $1.61. Autolus Therapeutics has a 12-month low of $1.11 and a 12-month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The company had revenue of $21.19 million for the quarter, compared to the consensus estimate of $21.08 million. On average, analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. R Squared Ltd boosted its stake in Autolus Therapeutics by 40.1% in the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after acquiring an additional 8,730 shares during the last quarter. Tema Etfs LLC lifted its stake in Autolus Therapeutics by 9.0% in the second quarter. Tema Etfs LLC now owns 120,388 shares of the company’s stock valued at $274,000 after purchasing an additional 9,960 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after purchasing an additional 11,289 shares during the period. Invesco Ltd. increased its position in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Autolus Therapeutics by 63.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock valued at $69,000 after buying an additional 11,821 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.